{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:11:07Z","timestamp":1793351467788,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jogc.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jogc.2018.05.046","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T08:25:45Z","timestamp":1542875145000},"page":"1497-1510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Michelle","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara L.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"McCuaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogc.2018.05.046_bib0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jogc.2018.05.046_bib0002","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","article-title":"Practice bulletin no 182: hereditary breast and ovarian cancer syndrome","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0003","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc2054","article-title":"Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations","volume":"7","author":"Fackenthal","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0004","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.24200","article-title":"BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer","volume":"115","author":"Hall","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0005","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jogc.2018.05.046_bib0006","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0007","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jogc.2018.05.046_bib0008","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jogc.2018.05.046_bib0009","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0010","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2018.05.046_bib0011","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/bjc.1995.417","article-title":"The genetics of breast and ovarian cancer","volume":"72","author":"Ford","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0012","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0013","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","article-title":"The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers","volume":"96","author":"Metcalfe","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0014","series-title":"Managing BRCA Mutation Carriers","first-page":"89","article-title":"Pathology of BRCA tumors","author":"Ibarra","year":"2017"},{"key":"10.1016\/j.jogc.2018.05.046_bib0015","series-title":"Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation","author":"Nelson","year":"2014"},{"key":"10.1016\/j.jogc.2018.05.046_bib0016","unstructured":"Surveillance, Epidemiology, and End Results Program, National Cancer Institute. Ovarian Cancer: Cancer Stat Facts. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html. Accessed on June 18, 2018."},{"key":"10.1016\/j.jogc.2018.05.046_bib0017","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2011.39.7638","article-title":"Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule","volume":"31","author":"Rosenthal","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0018","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"issue":"10022","key":"10.1016\/j.jogc.2018.05.046_bib0019","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(16)00631-0","article-title":"UKCTOCS and the evaluation of screening for ovarian cancer","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2018.05.046_bib0020","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000479155","article-title":"Evaluation of transvaginal ultrasound plus CA-125 measurement and prophylactic salpingo-oophorectomy in women at different risk levels of ovarian cancer: the Modena Study Group Cohort Study","volume":"93","author":"Cortesi","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.jogc.2018.05.046_bib0022","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/bcr3138","article-title":"Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"14","author":"Kotsopoulos","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jogc.2018.05.046_bib0023","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ijc.21273","article-title":"Effect of pregnancy as a risk factor for breast cancer in BRCA1\/BRCA2 mutation carriers","volume":"117","author":"Cullinane","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0024","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2214\/AJR.12.9845","article-title":"Breast imaging of the pregnant and lactating patient: physiologic changes and common benign entities","volume":"200","author":"Vashi","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0025","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.fertnstert.2013.01.109","article-title":"Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation","volume":"99","author":"Finch","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2018.05.046_bib0026","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2009.24.2057","article-title":"Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast\/ovarian cancer risks","volume":"28","author":"Oktay","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0027","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/01.ogx.0000489566.21546.e2","article-title":"Anti-m\u00fcllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations","volume":"71","author":"Phillips","year":"2016","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.jogc.2018.05.046_bib0028","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.fertnstert.2017.07.555","article-title":"Association of germline BRCA mutations with impaired fertility preservation cycle outcomes","volume":"108","author":"Turan","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2018.05.046_bib0029","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.fertnstert.2013.08.012","article-title":"Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion","volume":"100","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2018.05.046_bib0030","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2012.47.7893","article-title":"Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation","volume":"31","author":"Valentini","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0031","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00404-016-4187-6","article-title":"Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women","volume":"294","author":"de la Noval","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jogc.2018.05.046_bib0032","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/bmt-2016-0009","article-title":"Fertility preservation in BRCA-mutated breast cancer patients","volume":"5","author":"Lambertini","year":"2016","journal-title":"Breast Cancer Manag"},{"key":"10.1016\/j.jogc.2018.05.046_bib0033","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1080\/14656566.2016.1199685","article-title":"News on the medical treatment of young women with early-stage HER2-negative breast cancer","volume":"17","author":"Lambertini","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jogc.2018.05.046_bib0034","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/annonc\/mdx285","article-title":"Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT","volume":"28","author":"Regan","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0035","unstructured":"Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE). ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02308085. Accessed on June 18, 2018."},{"key":"10.1016\/j.jogc.2018.05.046_bib0036","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S1470-2045(12)70321-2","article-title":"Preimplantation genetic diagnosis for mutated BRCA genes","volume":"13","author":"Wilkinson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0037","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10552-008-9175-0","article-title":"Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study","volume":"19","author":"Kotsopoulos","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jogc.2018.05.046_bib0038","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.fertnstert.2015.07.1162","article-title":"BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles","volume":"104","author":"Shapira","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2018.05.046_bib0039","first-page":"588","article-title":"Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners","volume":"32","author":"Gietel-Habets","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jogc.2018.05.046_bib0040","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/humrep\/deu034","article-title":"Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer","volume":"29","author":"Derks-Smeets","year":"2014","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jogc.2018.05.046_bib0041","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/humrep\/dem055","article-title":"Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer","volume":"22","author":"Menon","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jogc.2018.05.046_bib0042","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10549-009-0455-5","article-title":"Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study","volume":"120","author":"Figueiredo","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jogc.2018.05.046_bib0043","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jogc.2018.05.046_bib0044","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"94","author":"Narod","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2018.05.046_bib0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM200107263450401","article-title":"Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation","volume":"345","author":"Modan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2018.05.046_bib0046","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0047","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt431","article-title":"Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium","volume":"106","author":"Trabert","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2018.05.046_bib0048","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdu578","article-title":"Low-dose aspirin use and the risk of ovarian cancer in Denmark","volume":"26","author":"Baandrup","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0049","unstructured":"Canadian Cancer Trials Group. Gynecologic Disease Site. Available at: https:\/\/www.ctg.queensu.ca\/public\/gynecologic\/gynecologic-disease-site. Accessed on June 18, 2018."},{"key":"10.1016\/j.jogc.2018.05.046_bib0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2018.05.046_bib0051","article-title":"Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kotsopoulos","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2018.05.046_bib0052","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0053","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/pon.2041","article-title":"The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation","volume":"22","author":"Finch","year":"2011","journal-title":"Psychooncology"},{"key":"10.1016\/j.jogc.2018.05.046_bib0054","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.maturitas.2011.08.001","article-title":"Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review","volume":"70","author":"Finch","year":"2011","journal-title":"Maturitas"},{"key":"10.1016\/j.jogc.2018.05.046_bib0055","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2018.05.046_bib0056","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2018.05.046_bib0057","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaoncol.2015.0658","article-title":"Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"1","author":"Metcalfe","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0058","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2012.45.3571","article-title":"Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer","volume":"31","author":"Huzarski","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0059","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-013-2729-1","article-title":"The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation","volume":"142","author":"Valentini","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jogc.2018.05.046_bib0060","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0090-8258(03)00365-2","article-title":"BRCA1\/2-related ovarian cancers are of tubal origin: a hypothesis","volume":"90","author":"Piek","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0061","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0062","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0063","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ygyno.2013.12.009","article-title":"Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations","volume":"132","author":"Conner","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0064","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2013.01.029","article-title":"Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy","volume":"129","author":"Powell","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0065","doi-asserted-by":"crossref","unstructured":"Harmsen MG, Arts-de Jong M, Hoogerbrugge N, et al. Early salpingectomy (tubectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer. 201519;15:593.","DOI":"10.1186\/s12885-015-1597-y"},{"key":"10.1016\/j.jogc.2018.05.046_bib0066","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju410","article-title":"Ovarian cancer risk after salpingectomy: a nationwide population-based study","volume":"107","author":"Falconer","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2018.05.046_bib0067","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/AOG.0000000000001448","article-title":"Salpingectomy with delayed oophorectomy in BRCA1\/2 mutation carriers: estimating ovarian cancer risk","volume":"127","author":"Harmsen","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0068","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2013.03.027","article-title":"The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study","volume":"130","author":"Segev","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0069","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2006.08.004","article-title":"The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations","volume":"104","author":"Beiner","year":"2007","journal-title":"A prospective study. Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0070","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0071","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2014.05.020","article-title":"Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers","volume":"134","author":"Vyarvelska","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0072","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1006\/gyno.2002.6638","article-title":"Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy","volume":"85","author":"Colgan","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0073","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2009.12.023","article-title":"Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube","volume":"117","author":"Cass","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0074","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.29321","article-title":"Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer","volume":"121","author":"Walker","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fonc.2016.00108","article-title":"Ovarian cancer: the fallopian tube as the site of origin and opportunities for prevention","volume":"6","author":"George","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0076","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/01.AOG.0000187892.78392.3f","article-title":"BRCA-mutation\u2013associated fallopian tube carcinoma","volume":"106","author":"Cass","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0077","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1097\/PAS.0b013e3181bc6059","article-title":"Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol","volume":"33","author":"Rabban","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0078","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IGC.0b013e31821bc7e3","article-title":"Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol","volume":"21","author":"Powell","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0079","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2012.07.021","article-title":"Support of the \u201cfallopian tube hypothesis\u201d in a prospective series of risk-reducing salpingo-oophorectomy specimens","volume":"49","author":"Reitsma","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0080","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of The North American Menopause Society","volume":"24","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2018.05.046_bib0081","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0082","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ygyno.2005.07.110","article-title":"Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers","volume":"100","author":"Kotsopoulos","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0083","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2018.05.046_bib0084","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-016-3685-3","article-title":"Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study","volume":"155","author":"Kotsopoulos","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jogc.2018.05.046_bib0085","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0086","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0087","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2005.05.1896","article-title":"The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy","volume":"24","author":"Madalinska","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0088","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1021119405814","article-title":"Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer","volume":"1","author":"Elit","year":"2001","journal-title":"Fam Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0089","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/01.gme.0000233170.42174.37","article-title":"Estradiol and sexual function in postmenopausal women","volume":"13","author":"Dennerstein","year":"2006","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2018.05.046_bib0090","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ygyno.2008.11.039","article-title":"A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer","volume":"112","author":"Fang","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0091","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10689-011-9480-8","article-title":"Non-cancer endpoints in BRCA1\/2 carriers after risk-reducing salpingo-oophorectomy","volume":"11","author":"Cohen","year":"2012","journal-title":"Fam Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0092","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2008.09.028","article-title":"Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study","volume":"45","author":"Michelsen","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jogc.2018.05.046_bib0093","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ygyno.2011.04.004","article-title":"Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1\/2 mutation carriers","volume":"122","author":"Chapman","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0094","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/ENDO:24:3:255","article-title":"Hormone replacement in women with breast cancer: the HABITS study","volume":"24","author":"Brincat","year":"2004","journal-title":"Endocrine"},{"key":"10.1016\/j.jogc.2018.05.046_bib0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/02841860601034834","article-title":"Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer","volume":"46","author":"Rutqvist","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jogc.2018.05.046_bib0096","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2016.11.012","article-title":"Management of hot flashes in women with breast cancer receiving ovarian function suppression","volume":"52","author":"Leon-Ferre","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.jogc.2018.05.046_bib0097","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.maturitas.2014.01.007","article-title":"Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment: who benefits and how does it work","volume":"78","author":"Chilcot","year":"2014","journal-title":"Maturitas"},{"issue":"22","key":"10.1016\/j.jogc.2018.05.046_bib0098","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2003.04.131","article-title":"Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations","volume":"21","author":"Levine","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jogc.2018.05.046_bib0099","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jogc.2018.05.046_bib0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5152\/jtgga.2016.15223","article-title":"Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy","volume":"17","author":"Iavazzo","year":"2016","journal-title":"J Turk Ger Gynecol Assoc"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S170121631830522X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S170121631830522X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T17:57:43Z","timestamp":1734631063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S170121631830522X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":100,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S170121631830522X"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2018.05.046","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2018.05.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of Society of Obstetricians and Gynaecologists of Canada.","name":"copyright","label":"Copyright"}]}}